Biz Brief: Analysts Weigh In on CVS, Walgreen Dispute

Before you go, we thought you'd like these...
Before you go close icon
Earlier this week, CVS Caremark (CVS) said it would exclude Walgreen (WAG) from its pharmacy network following a dispute between the two. The decision is risky for both companies: Caremark could potentially lose business clients, while Walgreen could lose retail customers. Shares of both have come under some serious pressure this week.

Several analysts have weighed in. Thomas Weisel cut Walgreen from overweight to market weight and lowered its price target to $30 from $45. The analyst estimated the lost CVS sales would equate to roughly $4.6 billion in annual revenue. Barclays also lowered its price target on Walgreen from $36 to $27, but kept its equal weight rating, while UBS downgraded Walgreen from buy to neutral. And although CVS actually earned an upgrade from Caris, it couldn't bounce back.

On Friday, CVS shares were down 0.9% and Walgreen shares down 2.2% as of 1:45 p.m. Eastern.
Read Full Story

Markets

DJIA 20,624.05 4.28 0.02%
NASDAQ 5,838.58 23.68 0.41%
S&P 500 2,351.16 3.94 0.17%
DAX 11,812.24 55.22 0.47%
NIKKEI 225 19,251.08 16.46 0.09%
HANG SENG 24,146.08 112.34 0.47%
USD (per EUR) 1.06 0.00 -0.10%
USD (per CHF) 1.00 0.00 0.20%
JPY (per USD) 113.11 0.20 0.18%
GBP (per USD) 1.25 0.00 0.22%

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners